Tenofovir alafenamide/emtricitabine

DRUG3 trials

Sponsors

ViiV Healthcare, University of Colorado, Denver, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Conditions

HIV InfectionsHIV-1-infection

Phase 1

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

CompletedNCT03836729

ViiV HealthcareHIV Infections

Start: 2019-02-11End: 2019-04-30Updated: 2020-04-21

Phase 4

Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide

CompletedNCT04636437

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsHIV Infections

Start: 2021-07-27End: 2024-10-18Updated: 2025-07-02

Unknown Phase

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

CompletedNCT04301661

University of Colorado, DenverHIV-1-infection

Start: 2020-03-06End: 2021-12-17Updated: 2023-01-09

Related Papers

A 48-week, Randomized Controlled Trial of Doravirine for Individuals with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391).

2026-03-18

DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor–Based Regimen Switch Strategy to Manage Integrase Inhibitor–Related Weight Gain

Clinical Infectious Diseases2024-09-049 citations

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.

2021-05-1812 citations